Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Cardiovascular diseases are the most important causes of death in patients with chronic renal disease (CRD). Successful renal transplantation (RTx) corrects water and electrolyte disturbances and decreases or eliminates anaemia. It favourably influences cardiac haemodynamics and reduces risk of cardiovascular events. NT-proBNP plasma concentration is one of the prognostic and risk factors in such cases, whereas echocardiography that enables evaluation of the left atrium and ventricle allows detailed analysis of haemodynamic condition of the heart.
Aim: To analyse NT-proBNP plasma concentration and selected echocardiographic parameters in patients after RTx at various time intervals after the procedure.
Methods: Seventeen patients after RTx were included in the study (age 46.5+/-16 years, 7 men and 10 women). NT-proBNP plasma level measurements and echocardiography were performed immediately before and at 3 and 6 months after RTx. Additionally, these parameters were assessed in patients receiving cyclosporine A (CsA) and tacrolimus (TAC).
Results: NT-proBNP plasma level decreases significantly after RTx (initially 4369+/-2420, at 3 months 2056+/-576, at 6 months 1580+/-572 pg/ml). In the TAC group, a significant reduction was observed at 3 months (from 13291+/-3563 to 1845+/-1022 pg/ml). In patients treated with CsA reduction occurred at 6 months after RTx (from 9447+/-3369 to 1246+/-436 pg/ml). At six-month follow-up significant changes in ejection fraction were not found. However, a significant increase in LV mass in CsA patients was observed.
Conclusions: Reduction of NT-proBNP levels seems to be more the result of transplanted kidney function than of an improvement in circulation. Significant LV mass increase in CsA patients may be a result of higher blood pressure levels observed before and after RTx.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Systematic analyses uncover plasma proteins linked to incident cardiovascular diseases.
Protein Cell
August 2025
Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200433, China.
Cardiovascular disease (CVD) research is hindered by limited comprehensive analyses of plasma proteome across disease subtypes. Here, we systematically investigated the associations between plasma proteins and cardiovascular outcomes in 53,026 UK Biobank participants over a 14-year follow-up. Association analyses identified 3,089 significant associations involving 892 unique protein analytes across 13 CVD outcomes.
View Article and Find Full Text PDFPrevalence of Sleep-Disordered Breathing and Cheyne-Stokes Respiration in Patients With Atrial Fibrillation.
Rev Cardiovasc Med
August 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, 113-8421 Tokyo, Japan.
Background: Limited data are available regarding the prevalence of sleep-disordered breathing (SDB), particularly Cheyne-Stokes respiration (CSR), in patients with atrial fibrillation (AF) and left ventricular (LV) systolic dysfunction. Thus, this study aimed to investigate the prevalence of SDB and CSR, as well as the factors associated with these conditions, in patients with AF without LV systolic dysfunction.
Methods: Patients with paroxysmal and non-paroxysmal AF underwent echocardiography and cardiorespiratory polygraphy.
BRIDGE-DS study: evaluating the effectiveness and safety of dapagliflozin/sitagliptin combination in type 2 diabetes mellitus patients with heart failure.
Cardiovasc Endocrinol Metab
December 2025
Department of Endocrinology, Scientific Services, USV Pvt. Ltd, Mumbai, Maharashtra, India.
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
Multiple biomarkers risk score for accurately predicting the long-term prognosis of patients with acute coronary syndrome.
J Geriatr Cardiol
July 2025
Heart-center of Beijing Chao-Yang Hospital, Capital Medical University, Beijing Key Laboratory of Hypertension, Beijing, China.
Background: Biomarkers-based prediction of long-term risk of acute coronary syndrome (ACS) is scarce. We aim to develop a risk score integrating clinical routine information (C) and plasma biomarkers (B) for predicting long-term risk of ACS patients.
Methods: We included 2729 ACS patients from the OCEA (Observation of cardiovascular events in ACS patients).
Early diagnostic utility of BNP and NT-proBNP for cardioembolic stroke: A head-to-head comparison in the hyperacute and early acute phase.
J Clin Neurosci
August 2025
Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address:
Background: Cardioembolic (CE) stroke is a common and often severe subtype of ischemic stroke, but early and accurate differentiation from other stroke types remains challenging. Brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) have emerged as promising biomarkers, yet direct comparative studies evaluating their diagnostic utility in the hyperacute and early acute phase are limited.
Methods: This prospective study included 165 patients who presented with acute stroke symptoms within twenty-four hours of onset at a single tertiary center.